Document Detail


Paradoxic elevation of fibrinopeptide A after streptokinase: evidence for continued thrombosis despite intense fibrinolysis.
MedLine Citation:
PMID:  3624659     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Elevated levels of fibrinopeptide A, a marker of thrombin activity associated with acute myocardial infarction, have been found to decrease after administration of streptokinase when reperfusion occurs. In contrast, in patients without reperfusion and those with reocclusion after streptokinase therapy, fibrinopeptide A remains elevated. In the present study early serial measurements of fibrinopeptide A were used to further characterize this paradoxic increase in thrombin activity after streptokinase and to characterize its response to heparin. In 19 patients with acute myocardial infarction fibrinopeptide A was elevated to 82.3 +/- 43.5 ng/ml (mean +/- SE) before therapy. Thirty minutes after the initiation of streptokinase, fibrinopeptide A increased to 300.1 +/- 117.4 ng/ml (p less than 0.01), consistent with extensive thrombin activity. Fibrinopeptide A remained elevated until 15 minutes after a heparin bolus injection when levels decreased to 15% of the poststreptokinase value (49.2 +/- 13.3 ng/ml) (p less than 0.001). These data document a prompt paradoxic increase in thrombin activity after administration of streptokinase that may be responsible for failure of therapy in some patients.
Authors:
P R Eisenberg; L A Sherman; A S Jaffe
Related Documents :
8038019 - Streptokinase neutralisation titres up to 866 days after intravenous streptokinase for ...
806229 - Magnesium deficiency and cardiac disorders.
2195859 - Magnesium replacement therapy.
3711489 - Elevated serum d dimer: a degradation product of cross-linked fibrin (xdp) after intrav...
389259 - Randomised multicentre trial of early mobilisation after uncomplicated myocardial infar...
2191849 - Intravenous streptokinase. a reappraisal of its therapeutic use in acute myocardial inf...
15894769 - Increased risk of heart failure as a consequence of perioperative myocardial injury aft...
9144029 - Rapid and specific immunoassay for cardiac troponin i in the diagnosis of myocardial da...
20488919 - Incidence, correlates, and outcomes of acute, hospital-acquired anemia in patients with...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Journal of the American College of Cardiology     Volume:  10     ISSN:  0735-1097     ISO Abbreviation:  J. Am. Coll. Cardiol.     Publication Date:  1987 Sep 
Date Detail:
Created Date:  1987-10-06     Completed Date:  1987-10-06     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  8301365     Medline TA:  J Am Coll Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  527-9     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cardiomyopathies / blood,  drug therapy
Coronary Circulation / drug effects
Coronary Disease / drug therapy*
Coronary Thrombosis / chemically induced,  drug therapy*
Fibrinogen / blood*
Fibrinolysis*
Fibrinopeptide A / blood*
Humans
Streptokinase / adverse effects,  therapeutic use*
Grant Support
ID/Acronym/Agency:
HL 17646/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
25422-31-5/Fibrinopeptide A; 9001-32-5/Fibrinogen; EC 3.4.-/Streptokinase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Inferior ST segment changes during acute anterior myocardial infarction: a marker of the presence or...
Next Document:  Effect of prior myocardial infarction and extent and location of coronary disease on accuracy of exe...